TRANSTHERA-B (02617.HK): Clinical Data of Core Product Tiengrtinib Published in Nature Communications

NewTimeSpace · 2026/05/17 20:41 · By Xuran Lin

NewTimeSpace News: TransThera Sciences (Nanjing), Inc. (02617.HK) announced that exploratory clinical findings of its core product tiengrtinib as monotherapy and in combination with atezolizumab for advanced solid tumors have been published in Nature Communications (Impact Factor=15.7). Clinical data show that the objective response rate (ORR) of tiengrtinib monotherapy reached 16.7%, while the combination regimen achieved an ORR of 22.6%. It demonstrated prominent efficacy in cholangiocarcinoma patients, with an ORR of 30.8% under monotherapy.

NewTimeSpace News: TransThera Sciences (Nanjing), Inc.(02617.HK) released a voluntary announcement on May 17, 2026, announcing that clinical research results of its core product tiengrtinib have been formally published in Nature Communications.

Tiengrtinib is a selectively pan-kinase inhibitor, targeting FGFR1-3, JAK1/2, VEGFRs and Aurora A/B. This Phase Ib/II clinical trial conducted in China evaluated the efficacy of tiengrtinib monotherapy (Arm A, enrolling 53 patients with advanced solid tumors) and its combination with atezolizumab (Arm B, enrolling 31 patients with advanced biliary tract tumors).

Study results showed that the ORR was 16.7% in Arm A receiving monotherapy and 22.6% in Arm B receiving combination therapy, both presenting potent anti-tumor activity. In pre-specified exploratory subgroup analysis, tiengrtinib yielded remarkable outcomes in cholangiocarcinoma patients: the ORR hit 30.8% in 13 patients of Arm A and 25.0% in 28 patients of Arm B.

For cholangiocarcinoma patients harboring FGFR2 fusion mutations who progressed after prior FGFR inhibitor treatment, the ORR of tiengrtinib monotherapy stood at 66.7%. Among 20 cholangiocarcinoma patients previously treated with immune checkpoint inhibitors, the combination regimen achieved an ORR of 20.0% and a disease control rate (DCR) of 75.0%.

The above findings support further clinical development of tiengrtinib monotherapy and its combination with immunotherapy.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.

Tags：

TRANSTHERA-B 02617.HK clinical development